- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04814355
The Effect of Celecoxib on Neuroinflammation in MDD
November 20, 2023 updated by: Christine DeLorenzo, Stony Brook University
The Effect of Celecoxib on Neuroinflammation in MDD: PET Imaging of a Novel Treatment Target With [18F]FEPPA
Major depressive disorder (MDD) affects an estimated 350 million people worldwide and is a leading contributor to global disease burden.
Commonly used monoamine reuptake-inhibiting treatments for depression are suboptimal, resulting in only 30% of patients achieving remission.
This may be because monoamine dysfunction is not the primary pathophysiology in all MDD patients.
One avenue for the development of novel MDD treatments is through anti-inflammatory drugs; MDD is linked to a pro-inflammatory phenotype characterized by microglial activation, leading to the release of pro-inflammatory cytokines and upregulation of cellular markers including cyclooxygenase-2 (COX-2) and translocator protein (TSPO; a protein located on the outer membrane of microglia).
Relevant to this proposal, TSPO can serve as an in vivo marker of neuroinflammation using the newly developed positron emission tomography (PET) tracer for TSPO, [18F]FEPPA.
In support of this, a recent [18F]FEPPA PET study found that MDD patients in a current major depressive episode (MDE) had significantly higher TSPO binding in the prefrontal cortex (PFC), anterior cingulate cortex (ACC) and insula, relative to healthy controls.
The prefrontal cortex and ACC are both implicated in mood regulation whereas the insula is involved in interoceptive signaling, which is known to be abnormal in MDD.
Celecoxib, a selective COX-2 nonsteroidal anti-inflammatory drug (NSAID), is a promising new treatment for neuroinflammation in MDD.
Clinical studies have observed that, in a subset of depressed patients, celecoxib treatment reduced depression severity as assessed by the Hamilton Depression Rating Scale (HDRS).
While these findings demonstrate that celecoxib reduces symptom severity, PET imaging technology is critical for understanding how celecoxib affects the underlying pathophysiology of depression.
Here, the team will investigate neuroinflammation as an underlying pathology in depression and test whether neuroinflammation is reduced by celecoxib in MDD patients.
Specifically, in the proposed pilot study, MDD patients in a current MDE will receive [18F]FEPPA PET scans prior to and following 8 weeks of treatment with 400mg/day of celecoxib, with HDRS scores obtained at each time point.
The investigators hypothesize that following celecoxib treatment, patients will show a significant reduction in neuroinflammation in the PFC, ACC and insula, which will correlate positively with the reduction in depressive symptoms, as measured by the HDRS.
The proposed study will use novel imaging technology, [18F]FEPPA PET, to measure the effects of celecoxib on neuroinflammation in MDD patients.
Our results will help to 1) identify neuroinflammation as an underlying pathology in MDD and 2) test whether reduction of inflammation is the mechanism of action of celecoxib.
As such, the results of this study will aid in the development of targeted clinical treatments to improve remission rates in MDD patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
42
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Alexandra Checkers, MBA
- Phone Number: 631-638-0291
- Email: alexandra.checkers@stonybrookmedicine.edu
Study Locations
-
-
New York
-
Stony Brook, New York, United States, 11794-8101
- Recruiting
- Psychiatry Department at Stony Brook University
-
Contact:
- Alexandra Checkers, MBA
- Phone Number: 631-638-0291
- Email: alexandra.checkers@stonybrookmedicine.edu
-
Contact:
- Christine DeLorenzo, PhD
- Phone Number: 631-638-1523
- Email: christine.delorenzo@stonybrookmedicine.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria
- Age: 18-65
- Diagnosis of MDD and currently in a major depressive episode
- Capacity to give informed consent
- Score of at least 29 on the MADRS
Exclusion Criteria
- Low affinity binders (LABs) for TSPO Genotype
- Hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any component of the formulation; previous asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Heptic impairment, heart failure, severe renal impairment, recent GI bleed, history of peptic ulcer disease, anemia or any other contraindication for celecoxib
- Poor CYP2C9 metabolizer
- Currently taking medications that interact with celecoxib (digoxin, antihypertensives, diuretics, anticoagulant or anti-platelet treatment, including aspirin)
- Use of herbs, drugs, or medications with anti-inflammatory or immunomodulatory properties (within 5 half-lives of starting celecoxib treatment)
- Unlikely to tolerate medication washout or the medication-free period following washout
- Participant considered at significant risk for suicide
- ECT within 1 month
- High potential for excessive drug/alcohol use during the treatment period (excluding nicotine or cannabis)
- Significant active physical illness or neurological deficit that may affect brain functioning or imaging
- Any PET contraindications, including if study imaging will result in the participant receiving greater exposure than the research limit, or if participant is currently pregnant, breastfeeding, or planning to conceive during the course of study participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Celecoxib 400 mg
Patients will receive 400 mg/day of celecoxib for 8 weeks.
|
Patients will receive 400 mg/day of celecoxib for 8 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in neuroinflammation as measured by [18F]FEPPA PET.
Time Frame: Before and after 8 weeks of treatment with celecoxib.
|
Change in [18F]FEPPA VT (VT; volume of distribution: ratio of the concentration of radioligand in tissue to that in plasma at equilibrium)
|
Before and after 8 weeks of treatment with celecoxib.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hamilton Depression Rating Scale-17 (HAMD) score.
Time Frame: Before and after 8 weeks of treatment with celecoxib.
|
Comparison of Hamilton Depression Rating Scale-17 score at pretreatment and post-treatment.
Minimum score 0, maximum possible score 52, with remission defined as <=7.
The higher the score on the scale, the more severe the degree of depression.
|
Before and after 8 weeks of treatment with celecoxib.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Christine DeLorenzo, PhD, Stony Brook University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2018
Primary Completion (Estimated)
July 31, 2024
Study Completion (Estimated)
July 31, 2024
Study Registration Dates
First Submitted
March 22, 2021
First Submitted That Met QC Criteria
March 22, 2021
First Posted (Actual)
March 24, 2021
Study Record Updates
Last Update Posted (Estimated)
November 22, 2023
Last Update Submitted That Met QC Criteria
November 20, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Mood Disorders
- Inflammation
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Neuroinflammatory Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Celecoxib
Other Study ID Numbers
- 81741
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Celecoxib 400 mg
-
Hoffmann-La RocheCompletedRheumatoid ArthritisRussian Federation
-
Dr. Reddy's Laboratories LimitedXenoPort, Inc.Completed
-
Atea Pharmaceuticals, Inc.Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
Daiichi Sankyo, Inc.CompletedHealthy VolunteersUnited States
-
Humanis Saglık Anonim SirketiNovagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiCompleted
-
Medicines for Malaria VentureAbbVieCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedAsthma; Allergic RhinitisChina
-
GlaxoSmithKlineCompletedPsoriasisGermany, United Kingdom
-
CTI BioPharmaCovanceCompleted